Market Place
Sourcing Support
Merus, Halozyme Sign Global Pact to Develop Petosemtamab
17 Nov 2025 //
PR NEWSWIRE
Merus’ Petosemtamab Shows Strong Activity in Metastatic CRC
24 Oct 2025 //
GLOBENEWSWIRE
Merus Publishes Abstract on Petosemtamab in mCRC at AACR-NCI
14 Oct 2025 //
GLOBENEWSWIRE
Merus To Present Petosemtamab Data In mCRC At AACR-NCI-EORTC
13 Oct 2025 //
GLOBENEWSWIRE
Merus to Present at the 2025 Wells Fargo Healthcare Conference
28 Aug 2025 //
GLOBENEWSWIRE
Merus Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
04 Aug 2025 //
GLOBENEWSWIRE
Merus to Present at Upcoming Investor Conferences
27 May 2025 //
GLOBENEWSWIRE
Merus Hails `Unprecedented` Survival on Solid Tumor Bispecific
22 May 2025 //
PRESS RELEASE
Merus Announces Journal Publication on Petosemtamab Action
15 May 2025 //
GLOBENEWSWIRE
Merus to Present at BofA Securities 2025 Health Care Conference
08 May 2025 //
GLOBENEWSWIRE
Merus Announces Q1 2025 Financial Results and Business Update
07 May 2025 //
GLOBENEWSWIRE
Merus Abstract Accepted for 2025 ASCO Annual Meeting
23 Apr 2025 //
GLOBENEWSWIRE
Merus to Join Fireside Chat at Needham Healthcare Conference
01 Apr 2025 //
GLOBENEWSWIRE
Merus to Present at Upcoming Investors Conferences
25 Feb 2025 //
GLOBENEWSWIRE
Petosemtamab Gets FDA Breakthrough Nod For 1L PD-L1+ HNSCC
18 Feb 2025 //
GLOBENEWSWIRE
Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer
05 Feb 2025 //
GLOBENEWSWIRE
Merus & Biohaven To Co-Develop 3 Novel Bispecific ADC Programs
12 Jan 2025 //
GLOBENEWSWIRE
Merus Doses First Patient in Phase 2 Petosemtamab Trial
16 Dec 2024 //
GLOBENEWSWIRE
FDA approves Merus` therapy to treat lung, pancreatic cancers
05 Dec 2024 //
REUTERS
Merus`s FDA Approval of Bizengri for NRG1+ Pancreatic and NSCLC
04 Dec 2024 //
GLOBENEWSWIRE
Merus Receives FDA extension of PDUFA for zenocutuzumab
05 Nov 2024 //
GLOBENEWSWIRE
Merus Doses First Patient In Ph 3 Trial Of Petosemtamab
30 Sep 2024 //
GLOBENEWSWIRE
Merus Announces Abstract Accepted for ESMO Asia Congress 2024
17 Sep 2024 //
GLOBENEWSWIRE
Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC
08 Jul 2024 //
GLOBENEWSWIRE
Merus` MCLA-129 Shows Efficiency In METex14 NSCLC At ASCO 2024
03 Jun 2024 //
GLOBENEWSWIRE
Merus` MCLA-145 Mono/Combo Data In Solid Tumors At ASCO 2024
02 Jun 2024 //
GLOBENEWSWIRE
Merus: Petosemtamab Combo Robust Response, Safety In Head/Neck Cancer
28 May 2024 //
GLOBENEWSWIRE
Merus Petosemtamab Hnscc Abstract: 1L With Pembro At 2024 Asco
23 May 2024 //
GLOBENEWSWIRE
Merus Abstracts Published: For 2024 Asco Annual Meeting
23 May 2024 //
GLOBENEWSWIRE
Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA
13 May 2024 //
GLOBENEWSWIRE
Merus Q1 2024 Financials, Business Update
08 May 2024 //
GLOBENEWSWIRE
Merus` Zeno BLA For NRG1+ NSCLC, PDAC Accepted For Priority Review
06 May 2024 //
GLOBENEWSWIRE
Merus Abstracts Accepted for ASCO 2024 Presentation
24 Apr 2024 //
GLOBENEWSWIRE
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023
28 Feb 2024 //
GLOBENEWSWIRE
Merus Announces Publication of Abstracts on MCLA-129 for Presentation
26 Nov 2023 //
GLOBENEWSWIRE
Merus Announces Business Update Conference Call
15 Oct 2023 //
GLOBENEWSWIRE
Merus Announces Two Abstracts on Zenocutuzumab (Zeno) in NRG1-fusion NSCLC
28 Jul 2023 //
GLOBENEWSWIRE
FDA Grants Breakthrough Therapy Designation to Zenocutuzumab for NRG1+ PC
30 Jun 2023 //
ONCLIVE
Zenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the USFDA
29 Jun 2023 //
GLOBENEWSWIRE
Merusâ Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity
17 Apr 2023 //
GLOBENEWSWIRE
Merus Announces Publication of an Abstract on Petosemtamab at the AACR
14 Apr 2023 //
GLOBENEWSWIRE
